Sign In

Login

Password

Forgot Password ? Sign Up

Lipidapherese (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lipidapherese" in German language version.

refsWebsite
Global rank German rank
33nih.gov
4th place
7th place
3doi.org
2nd place
3rd place
1seidel-dietrich.de
low place
low place
1awmf.org
5,401st place
312th place
1zdb-katalog.de
123rd place
6th place
1aerzteblatt.de
3,043rd place
200th place
1g-ba.de
low place
1,618th place

aerzteblatt.de

awmf.org

doi.org

  • J. Leebmann, E. Roeseler, U. Julius, F. Heigl, R. Spitthoever, D. Heutling, P. Breitenberger, W. Maerz, W. Lehmacher, A. Heibges, R. Klingel: Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. In: Circulation. Band 128, Nummer 24, Dezember 2013, S. 2567–2576, ISSN 1524-4539. doi:10.1161/CIRCULATIONAHA.113.002432. PMID 24056686.
  • E. Roeseler, U. Julius, F. Heigl, R. Spitthoever, D. Heutling, P. Breitenberger, J. Leebmann, W. Lehmacher, P. R. Kamstrup, B. G. Nordestgaard, W. Maerz, A. Noureen, K. Schmidt, F. Kronenberg, A. Heibges, R. Klingel; Pro(a)LiFe-Study Group: Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: Prospective 5 years of follow-up and apolipoprotein(a) characterization. In: Arterioscler Thromb Vasc Biol. Band 36, Nr. 9, September 2016, S. 2019–2027, doi:10.1161/ATVBAHA.116.307983, PMID 27417585.
  • P. M. Moriarty, K. G. Parhofer, S. P. Babirak, M. A. Cornier, P. B. Duell, B. Hohenstein, J. Leebmann, W. Ramlow, V. Schettler, V. Simha, E. Steinhagen-Thiessen, P. D. Thompson, A. Vogt, B. von Stritzky, Y. Du, G. Manvelian: Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. In: European heart journal. Band 37, Nummer 48, Dezember 2016, S. 3588–3595, doi:10.1093/eurheartj/ehw388. PMID 27572070, PMC 5233802 (freier Volltext).

g-ba.de

  • G-BA Beschluss 2016 g-ba.de (PDF; 504 kB)

nih.gov

ncbi.nlm.nih.gov

  • S. M. Grundy, J. I. Cleeman, C. N. Merz, H. B. Brewer Jr., L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith Jr., N. J. Stone: National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. In: Circulation. Band 110, 2004, S. 227–239, PMID 15249516.
  • G. R. Thompson und U. K. Heart: LDL Apheresis Working Group: Recommendations for the use of LDL apheresis. In: Atherosclerosis. Band 198, 2008, S. 247–255, PMID 18371971.
  • G. R. Thompson, M. Barbir, D. Davies, P. Dobral, M. Gesinde, M. Livingston, P. Mandry, A. D. Marais, S. Matthews, C. Neuwirth, A. Pottle, C. le Roux, D. Scullard, C. Tyler, S. Watkins: Efficacy criteria and cholesterol targets for LDL apheresis. In: Atherosclerosis. Epub ahead of print, 2009, PMID 19589528.
  • T. Eisenhauer, V. W. Armstrong, H. Wieland, C. Fuchs, K. Nebendahl, F. Scheler: Selective continuous elimination of low density lipoproteins (LDL) by heparin precipitation: first clinical application. In: Trans Am Soc Artif Intern Organs. Band 32, 1986, S. 104–107, PMID 3778691.
  • J. W. Park, M. Merz, P. Braun: Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia. In: Atherosclerosis. Band 139, 1998, S. 401–409, PMID 9712348.
  • W. O. Richter, M. G. Donner, P. Schwandt: Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. In: Ther Apher. Band 3, 1999, S. 203–208, PMID 10427616.
  • M. Suckfüll: Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. In: The Lancet. Band 360, 2002, S. 1811–1817, PMID 12480357.
  • U. Julius, W. Metzler, J. Pietzsch, T. Faßbender, R. Klingel: Intraindividual comparison of two extracorporeal LDL apheresis methods: Lipidfiltration and HELP. In: Int J Artif Organs. Band 25, 2002, S. 1180–1188, PMID 12518963.
  • U. Julius, K. G. Parhofer, A. Heibges, S. Kurz, R. Klingel, H. C. Geiss: Dextran-Sulfate-Adsorption (DSA) of Atherosclerotic Lipoproteins from Whole Blood or Separated Plasma for Lipid-Apheresis - Comparison of Performance Characteristics with DALI and Lipidfiltration. In: J Clin Apher. Band 22, 2007, S. 215–223, PMID 17455220.
  • U. Julius, W. Metzler, J. Pietzsch, T. Faßbender, R. Klingel: Intraindividual comparison of two extracorporeal LDL apheresis methods: Lipidfiltration and HELP. In: Int J Artif Organs. Band 25, 2002, S. 1180–1188, PMID 12518963.
  • J. Y. Kim, J. S. Park, J. C. Park, M. E. Kim, D. H. Nahm: Double-filtration plasmapheresis for the treatment of patients with recalcitrant atopic dermatitis. In: Ther Apher Dial. Band 17, Nr. 6, Dezember 2013, S. 631–637, PMID 24330559.
  • U. Julius, K. G. Parhofer, A. Heibges, S. Kurz, R. Klingel, H. C. Geiss: Dextran-Sulfate-Adsorption (DSA) of Atherosclerotic Lipoproteins from Whole Blood or Separated Plasma for Lipid-Apheresis - Comparison of Performance Characteristics with DALI and Lipidfiltration. In: J Clin Apher. Band 22, 2007, S. 215–223, PMID 17455220.
  • R. Nowack, G. Wiedemann: Pancytopenia with severe Thrombocytopenia in a patient treated with twice-weekly LDL-apheresis by polyacrylate adsorption from whole blood. In: J Clin Apher. Band 25, 2010, S. 77–80, PMID 20101676.
  • S. Schmaldienst, S. Banyai, T. M. Stulnig, G. Heinz, M. Jansen, W. H. Hörl, K. Derfler: Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolemia. In: Atherosclerosis. Band 151, 2000, S. 493–499, PMID 10924726.
  • U. Julius, K. G. Parhofer, A. Heibges, S. Kurz, R. Klingel, H. C. Geiss: Dextran-Sulfate-Adsorption (DSA) of Atherosclerotic Lipoproteins from Whole Blood or Separated Plasma for Lipid-Apheresis - Comparison of Performance Characteristics with DALI and Lipidfiltration. In: J Clin Apher. Band 22, 2007, S. 215–223, PMID 17455220.
  • S. Banyai, J. Streicher, W. Strobl, H. Gabriel, M. Gottsauner-Wolf, M. Rohac, F. Weidinger, W. H. Hörl, K. Derfler: Therapeutic efficiency of lipoprotein (a) reduction by low-density lipoprotein immunoapheresis. In: Metabolism. Band 47, 1998, S. 1058–1064, PMID 9751233.
  • H. Borberg, A. Gaczkowski, V. Hombach, K. Oette, W. Stoffel: Treatment of familial hypercholesterolemia by means of specific immunoadsorption. In: J Clin Apher. Band 4, 1988, S. 59–65, PMID 3294230.
  • T. Bosch, B. Schmidt, W. Kleophas, V. Otto, W. Samtleben: LDL hemoperfusion – a new procedure for LDL-apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. In: Artif Organs. Band 21, 1997, S. 1060–1065, PMID 9335362.
  • M. Jansen, S. Banyai, S. Schmaldienst, A. Goldammer, M. Rohac, W. H. Hörl, K. Derfler: Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolemia. In: Wien Klin Wochenschr. Band 112, 2000, S. 61–69, PMID 10703153.
  • C. Otto, P. Kern, R. Bambauer, S. Kallert, P. Schwandt, K. G. Parhofer: Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. In: Artif Organs. Band 27, 2003, S. 1116–1122, PMID 14678426.
  • C. Otto, J. Berster, B. Otto, K. G. Parhofer: Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia. In: J Clin Apher. Band 22, 2007, S. 301–305, PMID 17935245.
  • B. M. Schamberger, H. C. Geiss, M. M. Ritter, P. Schwandt, K. G. Parhofer: Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. In: J Lipid Res. Band 41, 2000, S. 727–733, PMID 10787433.
  • A. A. Kroon, W. R. Aegevaeren, T. van der Werf u. a.: LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. In: Circulation. Band 15, 1996, S. 1826–1835, PMID 8635262.
  • P. Meier, E. Blanc: Long-term efficacy of lipoprotein apheresis in homozygous familial hypercholesterolemia. In: Nephrol Dial Transplant. Band 15, 2000, S. 738–740, PMID 10809830.
  • I. O. Opole, J. M. Belmont, A. Kumar, P. M. Moriarty: Effect of low-density lipoprotein apheresis on inflammatory and non inflammatory high-density lipoprotein cholesterol. In: Am J Cardiol. Band 100, 2007, S. 1416–1418, PMID 17950800.
  • U. Julius, W. Metzler, J. Pietzsch, T. Faßbender, R. Klingel: Intraindividual comparison of two extracorporeal LDL apheresis methods: Lipidfiltration and HELP. In: Int J Artif Organs. Band 25, 2002, S. 1180–1188, PMID 12518963.
  • C. Bergmark, A. Dewan, A. Orsoni u. a.: A novel function of lipoprotein (a) as a preferential carrier of oxidized phospholipids in human plasma. In: J Lipid Res. Band 49, 2008, S. 2230–2239, PMID 18594118.
  • S. Kiechl, J. Willeit, M. Mayr u. a.: Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes. Prospective Results From the Bruneck Study. In: Arterioscler Thromb Vasc Biol. Band 27, 2007, S. 1788–1795, PMID 17541022.
  • Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). In: Lancet. Band 344, 1994, S. 1383–1389, PMID 7968073.
  • J. Leebmann, E. Roeseler, U. Julius, F. Heigl, R. Spitthoever, D. Heutling, P. Breitenberger, W. Maerz, W. Lehmacher, A. Heibges, R. Klingel: Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. In: Circulation. Band 128, Nummer 24, Dezember 2013, S. 2567–2576, ISSN 1524-4539. doi:10.1161/CIRCULATIONAHA.113.002432. PMID 24056686.
  • E. Roeseler, U. Julius, F. Heigl, R. Spitthoever, D. Heutling, P. Breitenberger, J. Leebmann, W. Lehmacher, P. R. Kamstrup, B. G. Nordestgaard, W. Maerz, A. Noureen, K. Schmidt, F. Kronenberg, A. Heibges, R. Klingel; Pro(a)LiFe-Study Group: Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: Prospective 5 years of follow-up and apolipoprotein(a) characterization. In: Arterioscler Thromb Vasc Biol. Band 36, Nr. 9, September 2016, S. 2019–2027, doi:10.1161/ATVBAHA.116.307983, PMID 27417585.
  • P. M. Moriarty, K. G. Parhofer, S. P. Babirak, M. A. Cornier, P. B. Duell, B. Hohenstein, J. Leebmann, W. Ramlow, V. Schettler, V. Simha, E. Steinhagen-Thiessen, P. D. Thompson, A. Vogt, B. von Stritzky, Y. Du, G. Manvelian: Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. In: European heart journal. Band 37, Nummer 48, Dezember 2016, S. 3588–3595, doi:10.1093/eurheartj/ehw388. PMID 27572070, PMC 5233802 (freier Volltext).
  • R. Spitthöver, T. Röseler, U. Julius, F. Heigl, V. J. J. Schettler, R. Kühn, J. Leebmann, A. Raabe, M. Knittel, C. Schürfeld, M. Moesenthin, W. M. Bernhardt, E. Röseler, M. Ketteler, A. Heibges, R. Klingel: Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis. In: J Clin Apher. Band 34, Nr. 4, August 2019, S. 423–433, PMID 30817043.

seidel-dietrich.de

zdb-katalog.de

  • J. Leebmann, E. Roeseler, U. Julius, F. Heigl, R. Spitthoever, D. Heutling, P. Breitenberger, W. Maerz, W. Lehmacher, A. Heibges, R. Klingel: Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. In: Circulation. Band 128, Nummer 24, Dezember 2013, S. 2567–2576, ISSN 1524-4539. doi:10.1161/CIRCULATIONAHA.113.002432. PMID 24056686.